Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · KIMS

KIMS

HealthcareHealthcare Services₹30262 cr market cap
₹767.80 ▲ +1.16% today As of 19 Nov 2026
52-week low ₹582.1052-week high ₹850.65

-10.8% from the 52-week high · +30.4% above the low

Krishna Institute of Medical Sciences Ltd. engages in the provision of healthcare services. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2021-06-28. The Company’s departments include accident, Alzheimer center, andrology and infertility center, pediatric obesity, pediatric oncology, pediatric oncology and hematology center, pediatric orthopedics and rheumatology, pediatric renal center, pediatric surgical center, female urology center, fertility center, gastrointestinal oncology, general surgery, heart wellness center and hepatobiliary surgery center. Its technologies include 4-Arm HD da Vinci Robotic Surgical System, O-Arm Scanner, Novalis Tx Linear Accelerator, 3 Tesla MRI, EBUS, Spy Glass, Mako Robotic for Knee Replacement, and Impella. The Company’s institutes include the institute of Cardiac Sciences, Institute of Dental Science, Institute of Gastroenterology & Hepatology, Institute of Heart & Lung Transplantation, and Institute of Neuro Sciences.

The short version. KIMS reported revenue of ₹1,344 crore for Sep 2026, up 39.9% from a year earlier. Net profit was ₹75 crore (up 11.9% year on year). Return on equity was 10.7% in Mar 2026. Promoter holding was 32.66% in Sep 2026, down 6.16 points over 8 quarters.

1 · The price

How has the stock traded?

KIMS trades 10.8% below its 52-week high and 30.4% above its 52-week low.

Change over period: —

1M+11.9%
3M-3.8%
6M+0.4%
1Y+13.6%

2 · The business

Is it growing?

Sales, year on year+39.9%

Sep 2026 revenue of ₹1,344 cr.

Profit, year on year+11.9%

Sep 2026 net profit of ₹75 cr.

Net margin5.6%

1.4 pts lower than a year earlier.

3-year growth-10.5% profit

Revenue compounded at 20.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue134411801075998961872797772
Net profit75424253677910292
Net margin %5.63.54.05.47.09.012.812.0
EPS (₹)1.790.991.061.331.681.962.542.31

Annual

FY2026FY2025FY2024FY2023FY2022FY2021
Revenue390530352498219816511330
Net profit241384310336333201
Net margin %6.212.712.415.320.215.1
EPS (₹)6.039.617.758.418.315.03

3 · The quality

How well does it turn capital into profit?

Return on equity was 10.7% in Mar 2026; debt to equity is 1.44.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %10.718.017.020.1
Return on capital %8.213.214.919.5
EBITDA margin %20.826.926.029.0
Net margin %6.112.512.315.1

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR20.9%24.0%
Profit CAGR-10.5%3.7%
Debt to equity1.44
Interest cover2.6x
Current ratio0.76
P/E ratio145.1

4 · The owners

Who holds it, and are they adding?

Promoter holding32.66%

Down 6.16 pts over 8 quarters.

Foreign institutions15.01%

Down 0.67 pts over 8 quarters.

Domestic institutions33.22%

Up 1.17 pts over 8 quarters.

Mutual fund schemes144

+35 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter38.8238.8234.1134.1134.1134.1132.532.66-6.16
FII15.6815.4515.5415.0314.3314.5714.7415.01-0.67
DII32.0531.9531.6632.1232.7132.534.4333.22+1.17
Public13.4513.7818.6918.7418.8518.8218.3319.11+5.66

Mutual fund holdings · Oct 2026

144 schemes hold this stock

109 the month before.

  • Groww BSE Hospitals ETF8.56% of NAV
  • Invesco India Pharma and Healthcare Fund4.38% of NAV
  • Mirae Asset Healthcare Fund3.48% of NAV
  • Kotak Small Cap Fund3.31% of NAV
  • Invesco India Small cap Fund3.2% of NAV
  • Kotak Business Cycle Fund3.09% of NAV
  • Axis Services Opportunities Fund2.98% of NAV
  • Axis Flexi Cap Fund2.9% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for KIMS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about KIMS

What is the KIMS share price?

KIMS (KIMS) last closed at ₹767.80, up 1.16% on the day. Its 52-week range is ₹582.10 to ₹850.65.

What is the market cap of KIMS?

KIMS has a market capitalisation of about ₹30,262 crore. Its price-to-earnings ratio is 145.1.

How are KIMS's latest results?

KIMS reported revenue of ₹1,344 crore for Sep 2026, up 39.9% from a year earlier. Net profit was ₹75 crore (up 11.9% year on year). Return on equity was 10.7% in Mar 2026. Promoter holding was 32.66% in Sep 2026, down 6.16 points over 8 quarters.

Who owns KIMS?

As of Sep 2026, shareholding was: Promoter 32.66%, FII 15.01%, DII 33.22%, Public 19.11%.

How many mutual funds hold KIMS?

144 mutual fund schemes held KIMS in October 2026. That compares with 109 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 13 Sep 2024 · Stock Split From Rs.10/- to Rs.2/-

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.